A
AMYLYX PHARMACEUTICALS INC
NASDAQ: AMLX (Amylyx Pharmaceuticals, Inc.)
Last update: yesterday, 6:40PM28.86
0.18 (0.63%)
| Previous Close | 28.68 |
| Volume | 989,514 |
| Price / Book | 13.35 |
| 52 Weeks Range |
| Operating Margin (TTM) | 16,317.06% |
| Diluted EPS (TTM) | -3.10 |
| Quarterly Revenue Growth (YOY) | -99.60% |
| Total Debt/Equity (MRQ) | 0.69% |
| Current Ratio (MRQ) | 12.05 |
| Operating Cash Flow (TTM) | -206.98 M |
| Levered Free Cash Flow (TTM) | -182.62 M |
| Return on Assets (TTM) | -40.72% |
| Return on Equity (TTM) | -83.24% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Mixed | |
| Stock | Amylyx Pharmaceuticals, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | -1.6 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.0 |
| Relative Valuation | NA |
| Financial Health | 0.0 |
| Macro Environment | -0.3 |
| AI Insight | NA |
| AI Technical | NA |
| Weighted Average | -0.70 |
Select this tab to load the latest available analysis.
|
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder and endocrine conditions. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Growth |
| % Held by Insiders | 9.54% |
| % Held by Institutions | 85.89% |
No data within this time range.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |